Bioventus Inc. provided preliminary unaudited earnings guidance for the first quarter of 2022. For the period, the company expects net sales to be in the range of $116.5 million to $118.5 million, reflecting 42% to 45% growth over the prior-year period. Net loss expects to be in the range of $19,000,000 and $19,400,000.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.215 USD | +0.89% | -1.42% | +18.79% |
May. 07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
May. 07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.79% | 393M | |
+75.33% | 12.38B | |
-20.33% | 7.76B | |
+7.70% | 6.61B | |
+12.78% | 5.4B | |
+37.02% | 4.96B | |
-17.50% | 4.75B | |
-24.72% | 3.89B | |
-28.10% | 2.66B | |
+57.80% | 2.45B |
- Stock Market
- Equities
- BVS Stock
- News Bioventus Inc.
- Bioventus Inc. Provides Preliminary Unaudited Earnings Guidance for the First Quarter of 2022